Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1503 of 6351
-
Blood tests may one day replace sleep studies for apnea
Knowledge-focused Recruiting nowObstructive sleep apnea (OSA) is a common sleep disorder associated with intermittent hypoxia, systemic inflammation, oxidative stress, and an increased risk of cardiovascular and metabolic diseases. Current diagnostic methods are effective but have limited availability and do no…
Sponsor: Medical University of Bialystok • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
One shot to rule them all? new combo vaccine trial for kids begins
Vaccine Recruiting nowThis clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two utilizes a randomized, blinded, placebo-controlled design. Part One is divided into four stages based on age and vaccine …
Phase 1 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Jun 27, 2026 08:07 UTC
-
Heart stent showdown: which medicated device keeps arteries open best?
Disease control Recruiting nowTo evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention). To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of is…
Sponsor: Fundación EPIC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Supercharged immune cells take on Hard-to-Treat head and neck cancer
Disease control Recruiting nowTo find the recommended dose of an investigational therapy called chimeric antigen receptor (CAR).TROP2/interleukin (IL)15-transduced TGFBR2 KO cord blood (CB)-derived natural killer (NK) cells (TROP2 CAR/IL-15 TGFBR2 KO NK cells) that can be given with and without preconditionin…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug ravulizumab aims to control rare blood disorder aHUS
Disease control Recruiting nowThe primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).
Phase 4 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Smart watch for the heart: can remote monitoring save lives?
Disease control Recruiting nowThis randomized, controlled, open-label, parallel, multicenter clinical study evaluates the efficacy of SmartSignalHF compared with heart failure (HF) remote monitoring (RM) standard of care in implanted patients with heart failure. The primary objective is to determine whether S…
Sponsor: Implicity • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug combo aims to ease muscle weakness in myasthenia gravis
Disease control Recruiting nowThis study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patie…
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for advanced kidney cancer: first human trial of NEO-811 begins
Disease control Recruiting nowThe NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 init…
Phase 1 • Sponsor: Neomorph, Inc • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThis is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to test the effects of the drugs on cancer. Cohort A will receive talquetamab + dexamethasone, then mezigdomide + talquetamab,+…
Phase 1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Hormone implants could ease menopause symptoms for years
Symptom relief Recruiting nowEstrogen and androgen deficiencies negatively impact the quality of life of women at different stages of life, especially after menopause. New modalities and new therapeutic alternatives have been researched. Parenteral administration of estradiol and testosterone could be effect…
Phase 3 • Sponsor: University of Sao Paulo General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Could a simple pill tame long COVID's immune chaos?
Disease control Recruiting nowLong COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID. Long COVID Postural Orthostatic Tachy…
Phase 2 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New depression pill icalcaprant enters Mid-Stage trial
Symptom relief Recruiting nowMajor depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focu…
Phase 2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New pill aims to tackle two common conditions at once
Disease control Recruiting nowThis clinical trial is a randomized, active controlled, double blind, parallel, multi center, phase 3 study to evaluate the efficacy and safety of monotherapy group of HL1113R1 or HL1113R2 versus HL1113 (Fixed dose combination) in patients with essential hypertension and type II …
Phase 3 • Sponsor: Hanlim Pharm. Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Old malaria and HIV drugs repurposed to fight ovarian cancer
Disease control Recruiting nowThis is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and nelfinavir mesylate (NFV) will benefit ovarian cancer patients in a maintenance setting. Patients will receive t…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Engineered virus targets Hard-to-Treat cancers in early trial
Disease control By invitation onlyThis is an open-label, dose escalation, phase I study to evaluate safety tolerability, MTD or MFD, pharmacokinetic profile, immunogenicity, and pharmacodynamic profile of IDOV-Immune in patients with advanced solid tumors.
Early phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced colorectal cancer: EMB-01 trial launches
Disease control Recruiting nowThis study is testing different dosing schedules of EMB-01 in patients with advanced colorectal cancer whose disease has recurrent or progressed on previous treatments. Patients will be randomly assigned to one of two dosing schedules: EMB-01 once weekly, or once weekly for 6 wee…
Phase 2 • Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cell therapy trial targets hard-to-treat solid tumors
Disease control Recruiting nowThis is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objecti…
Early phase 1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New home scanner could keep heart failure patients out of hospital
Disease control Recruiting nowThis study will evaluate the Heartfelt device, a novel, passive monitoring system that detects early signs of fluid build-up in patients (oedema) with heart failure by measuring changes in foot and lower leg volume through capture of 3D images. The trial will assess whether this …
Sponsor: Heartfelt Technologies • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could an arthritis pill ease Sjogren's? new trial seeks answers
Disease control Recruiting nowBackground: Sjogren disease is an autoimmune disease - that is, a disease that causes the body's immune system to attack its own organs and tissues. Sjogren disease can affect the kidneys, lungs, or other organs. It can also cause dry mouth and eyes, fever, joint pain, rashes, a…
Phase 2 • Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Rural teens get depression help through mentor training study
Prevention Recruiting nowThis study will evaluate the usability, feasibility, and acceptability of a novel multi-level Just-In-Time Training (JITT) implementation strategy (JITT-EBP) that aims to equip mentors and mentor supervisors to implement evidence-based practices (EBPs) with fidelity using methods…
Sponsor: University of Minnesota • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC